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Abstract
Importance of the field—Transdermal delivery of macromolecules provides an attractive
alternative route of drug administration when compared to oral delivery and hypodermic injection,
because of its ability to bypass the harsh gastro-intestinal tract and deliver therapeutics non-
invasively. However, the barrier properties of the skin only allow small, hydrophobic permeants to
traverse the skin passively, greatly limiting the number of molecules that can be delivered via this
route. The use of low-frequency ultrasound for the transdermal delivery of drugs, referred to as
low-frequency sonophoresis (LFS), has been shown to increase skin permeability to a wide range
of therapeutic compounds, including both hydrophilic molecules and macromolecules. Recent
research has demonstrated the feasibility of delivering proteins, hormones, vaccines, liposomes,
and other nanoparticles through LFS-treated skin. In vivo studies have also established that LFS
can act as a physical immunization adjuvant. LFS technology is already clinically available for use
with topical anesthetics, with other technologies currently under investigation.
Areas covered in this review—This review provides an overview of mechanisms associated
with LFS-mediated transdermal delivery, followed by an in-depth discussion of the current
applications of LFS technology for the delivery of hydrophilic drugs and macromolecules,
including its use in clinical applications.
What the reader will gain—The reader will gain insight into the field of LFS-mediated
transdermal drug delivery, including how use of this technology can improve upon more
traditional drug delivery methods.
Take home message—Ultrasound technology has the potential to impact many more
transdermal delivery platforms in the future, due to its unique ability to enhance skin permeability
in a controlled manner.
1. Introduction
The delivery of macromolecules or hydrophilic drugs has long been a desired goal in
transdermal drug delivery. This is due to the fact that the skin provides an attractive
alternative route of drug administration compared to oral delivery and hypodermic
injections. With respect to oral delivery, advantages include: (i) minimization of first-pass
metabolic effects, (ii) bypassing of the harsh gastro-intestinal tract that can cause
degradation or denaturing of macromolecules, and (iii) decreased side effects from dyspeptic
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drugs.1, 2 Furthermore, advantages of transdermal delivery over hypodermic injections
include: (i) non-invasive delivery, (ii) decreased pain and increased patient compliance, (iii)
decreased generation of dangerous medical sharps, and (iv) less risk of needle
contamination, disease transmission, and needle misuse.1, 2 Transdermal delivery also
allows for sustained release profiles for both systemic or localized drug delivery, which is
not always possible with oral or injectable formulations. However, the innate structure of the
skin provides a very robust barrier to drug delivery. In fact, only very small and hydrophobic
molecules, such as clonidine, estradiol, fentanyl, nicotine, nitroglycerine, scopolamine, and
testosterone, have been successfully administered at therapeutic levels through intact skin.1,
2 This has led to the so-called “500 Dalton Rule”, which states that for a drug to be
deliverable through native skin, it must have a molecular weight of less than 500 Daltons
and, in general, be hydrophobic.3 The reason for these limitations is that the primary barrier
for transdermal transport is the outermost layer of the epidermis, the stratum corneum,
which is typically only 10–20 μm in thickness (see Figure 1). The stratum corneum is a non-
viable cell layer that is comprised of highly-crosslinked keratinocytes (or corneocytes),
embedded in a continuous matrix of skin lipids (see Figure 2).
To deliver high-molecular weight or hydrophilic drugs, one can generally use one of two
approaches. First, if the drug being administered is sufficiently small, chemical modification
can be utilized to increase its lipophilicity, without directly affecting the structure of the
skin.4 Furthermore, one can also increase the driving force for permeation using various
strategies, including supersaturation of the delivery vehicle, increasing the vehicle-to-skin
partition coefficient, or by electroosmotic flow induced by iontophoresis, without directly
affecting the skin structure.5 Conversely, one can use a chemical or physical enhancer to
decrease the barrier properties of the skin without modifying the drug itself. Chemical
enhancers include molecules such as surfactants or oils, and operate by denaturing
keratinocytes, disordering/fluidizing lipid bilayers, or creating segregated phases in the
stratum corneum.1, 2 There are many types of physical enhancers for transdermal delivery,
such as iontophoresis (application of a continuous, low-voltage electric field),6
electroporation (application of pulsed, high-voltage electricity),6 thermal or laser ablation,7
liquid or powder jet injectors,8 or the use of high- or low-frequency ultrasound
(sonophoresis). Low-frequency sonophoresis (LFS), in particular, offers advantages over
other transdermal delivery methods. Specifically, with LFS, the extent of skin perturbation,
and the resulting skin permeability enhancement, can be controlled by varying the
application time and other ultrasound parameters.9–13 Therefore, systemic, regional, and
local delivery are possible with LFS. The size of aqueous skin pores created by LFS can also
be controlled by varying the frequency and the intensity of the ultrasound utilized.11, 14
Moreover, LFS allows for pretreatment of the skin, prior to application of a drug-containing
patch, so that the actual LFS treatment is only on the order of seconds and the device does
not need to be worn constantly.15–18 Finally, LFS has shown promise in delivering both
macromolecules and hydrophilic permeants transdermally,19, 20 as well as in non-invasively
monitoring blood analytes, such as blood glucose.21, 22 In this review, the mechanisms and
phenomena associated with LFS will be highlighted, followed by a more rigorous analysis
of both theoretical and experimental studies on the delivery of large and hydrophilic
permeants with LFS. Commentary will also be provided on the current clinical status of
LFS, including a critical discussion of what the future holds for LFS-assisted transdermal
drug delivery.
2. Background
Although the use of therapeutic (0.7 – 3 MHz) and high-frequency (> 3MHz) ultrasound for
medical applications, including transdermal drug delivery, goes back many decades, the use
of low-frequency ultrasound (20 – 100 kHz) for transdermal delivery is still in its relative
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infancy, spanning only the last two decades. Initial studies utilizing LFS were reported in the
early 1990s, by Tachibana et al., who utilized 105 kHz and 48 kHz ultrasound to
transdermally deliver insulin and lidocaine to rabbits and hairless mice.23–25 Shortly
thereafter, Mitragotri et al. demonstrated that LFS could be utilized to deliver even higher
molecular weight proteins, such as interferon γ (~17,000 Da) and erythropoietin (~48,000
Da).19 Additional work showed that LFS is up to three orders of magnitude more effective
in inducing transdermal transport than therapeutic ultrasound.26 Therefore, this review will
focus only on the mechanisms and applications of low-frequency ultrasound-mediated
transdermal drug delivery.
2.1 Mechanisms
After it was established that LFS is significantly more effective at increasing skin
permeability than ultrasound at therapeutic frequencies, the next major goal in the field was
to achieve a better mechanistic understanding of skin perturbation by LFS. Note that the
mechanisms of LFS depend on the treatment protocol utilized. Two protocols have been
reported in the literature: (i) the simultaneous protocol, with a drug included in the LFS
coupling medium, or (ii) the pretreatment protocol, which involves the application of LFS
followed by the passive delivery of a drug to the skin in a patch or other formulation. The
pretreatment protocol tends to be used more often than the simultaneous protocol in more
recent studies involving LFS-mediated delivery of macromolecules.27–32 This is because
the simultaneous protocol requires that the ultrasound device be constantly applied to the
skin during treatment, which can cause degradation of the drug compound in the coupling
medium, thus providing an additional limitation in comparison to the pretreatment protocol.
33, 34 However, some recent studies have also used the simultaneous protocol with a
miniaturized LFS device, utilizing a degassed coupling medium in order to minimize the
effects of compound degradation.35–41
The first mechanistic investigations of LFS involved the use of acoustic spectroscopy to
gauge the importance of cavitation as an enhancing mechanism. In these experiments, Tang
et al. and Tezel et al. showed conclusively that inertial acoustic cavitation is the primary
mechanism of LFS-induced skin permeability enhancement.42, 43 Furthermore, by
selectively suppressing cavitation in the bulk coupling medium and in the entire system,
Tang et al. were able to demonstrate that only cavitation above the skin, in the aqueous
coupling medium, is responsible for skin permeability enhancement by LFS.42 Additional
studies followed that established that cavitation in the vicinity of the skin surface, likely as
transient cavitation microjets directed at the skin surface, is the most likely contributor to
skin permeability enhancement.44 For a deeper discussion of the physics of ultrasound and
cavitation, the reader is referred to the review by Leighton.45 Although cavitation within the
skin itself can play a role at therapeutic ultrasound frequencies (> 0.7 MHz),46 it does not
play a role in skin permeability enhancement with LFS.42 Unfortunately, these mechanisms
are sometimes confused, leading to incorrect citations. For example, several recent reviews
and papers have referenced sonophoresis studies utilizing therapeutic frequencies, or
incorrectly cited LFS studies, to state that only cavitation within the skin plays an important
role in LFS-mediated transdermal drug delivery.47–49
With the simultaneous protocol, in addition to the cavitational effects discussed above,
convective processes can also play a role. For example, Tang et al. have shown that
convection can cause increased drug transport in heat-stripped skin, although it does not
play a role in thicker skin models such as split-thickness skin (700 μm) and full-thickness
skin models.20 Furthermore, Tachibana et al. have shown that convection can play a role in
the transdermal delivery of lidocaine with LFS.25 However, other studies have concluded
that convection does not play a role with LFS.10 Therefore, the role of convection as an
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enhancing mechanism in LFS, especially in comparison to cavitation, is still not completely
understood.
2.2 Localized Transport
A shift in the mechanistic understanding of LFS occurred when it was observed that skin
permeability enhancement occurs primarily in discrete regions of the skin,50, 51 and not
uniformly across the entire skin surface. These highly-perturbed regions (see Figure 3),
referred to as localized-transport regions (LTRs), have been shown to be up to three orders
of magnitude more permeable than untreated skin.14, 52, 53 In addition, when a chemical
enhancer, such as the surfactant sodium lauryl sulfate (SLS), is included in the LFS coupling
medium, it has been shown that even the less-perturbed non-LTRs possess increased
transport properties with respect to untreated skin, although to a considerably smaller extent
than the highly-perturbed LTRs.14, 52 Recently, it has been shown that the mechanisms of
enhancement within LTRs and non-LTRs are different.14 By studying the average aqueous
pore radii (see Section 3.1) within each skin region at multiple LFS frequencies (20, 40, and
60 kHz), in the presence of SLS, it was shown that pore radii within LTRs are strongly
frequency dependent, while pore radii within non-LTRs exhibit no frequency dependence.
This suggests that a frequency-dependent process, such as the collapse of transient cavitation
microjets at the skin surface, is responsible for the observed enhancement within the LTRs,
while the frequency-independent process of SLS acting on the skin is the main mechanism
of enhancement within the non-LTRs.14
2.3 Synergism between LFS and Surfactants
It is well known that using multiple skin penetration enhancers, both chemical and physical,
can lead to synergistic skin permeability enhancement. For example, chemical enhancers are
known to enhance skin permeability through their interaction with lipid bilayers or via the
denaturation of corneocytes.2 However, many chemical enhancers are limited in their ability
to penetrate into the skin, and are therefore limited in inducing more substantial permeability
enhancement, due to the natural barrier properties of the stratum corneum. Therefore, if a
second enhancer is used that can not only increase the permeability of the skin itself, but can
also increase the penetration of the first enhancer, a much larger effect is often observed in
the combined case compared to either enhancer alone. This mechanism has been shown to
be particularly significant in the case of the synergism observed between LFS and
surfactants. For example, Mitragotri et al. have shown that the synergism between LFS and
SLS occurs because of increased SLS penetration and dispersion in the skin as a result of the
LFS application.54 In a subsequent study, Tezel et al. investigated the synergism between
LFS and a group of fourteen separate surfactants.54, 55 Their findings showed that if skin is
treated with a given surfactant for a sufficiently long time, the skin permeability
enhancement induced by the surfactant alone will approach the enhancement induced by the
combination of the surfactant and LFS. This suggests that LFS-induced penetration of
surfactant into the skin plays a central role in the observed synergism between chemical
enhancers and LFS.55 Other mechanisms have also been studied to elucidate the synergism
between LFS and surfactants, such as shifts in the pH profile of the skin as a result of the
LFS/SLS treatment.56 However, in spite of these observations, to date, there has been no
physical mechanism proposed that demonstrates how LFS causes increased penetration of
surfactants into the skin. Therefore, the synergism between LFS and surfactants is still not
fully understood, and represents a fertile area of ongoing research.
The synergism between LFS and surfactants also has implications on the clinical viability of
ultrasound-mediated transdermal drug delivery. For example, it has been demonstrated that
the treatment time and energy density required to induce significant skin permeability
enhancement are decreased by nearly an order of magnitude when SLS is combined with
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LFS.54, 55 This allows patients to be treated for much shorter periods of time and with less
intense ultrasound protocols, which is extremely beneficial for the practical use of LFS.
Moreover, a recent study has shown that the combined LFS/SLS treatment of skin may, in
fact, be less perturbing to the skin than that using LFS alone.57 Although this finding is not
intuitive, because it would be expected that the combination of a physical and a chemical
enhancer should induce more skin perturbation than a physical enhancer alone, it reflects the
times required to reach similar extents of skin permeability using each treatment.57
Specifically, because the LFS treatment alone takes nearly an order of magnitude more time
to reach similar extents of skin permeability than the LFS/SLS treatment, skin samples are
subjected to a much harsher treatment when only LFS is utilized. Furthermore, it was shown
that skin samples treated by LFS/SLS yielded much more predictable and reproducible skin
permeability values than those treated with LFS alone, a finding which is clearly more
desirable in a clinical setting.57 For these reasons, the combination of LFS and a chemical
enhancer is nearly always utilized in LFS treatment protocols, particularly in clinical settings
or when delivering large or hydrophilic permeants.
3. Delivery of Hydrophilic Permeants with LFS
3.1 The Aqueous Porous Pathway Model
Although traditional transdermal transport models have typically utilized molecular weight
and octanol-water partition coefficients (logKo/w) to describe solute transport through the
skin, including transport of hydrophilic permeants,58, 59 an improved mechanistic
understanding of hydrophilic permeant transport through LFS-treated skin was made
possible by the development of the aqueous porous pathway model (APPM).20 By assuming
that hydrophilic permeants traverse the stratum corneum along the same pathways as the
current carrying ions, the APPM derives a quantitative relationship between the skin
permeability of hydrophilic permeants, P, and the skin electrical resistivity, R. Specifically,
by utilizing relations from hindered-transport theory for the diffusion of permeants through
confined pores,60 the APPM demonstrates that a linear regression of log P versus log R
should yield a slope of −1.20 Moreover, by substituting the values of known parameters
associated with the bulk solution, the skin membrane, and the diffusing permeant
(hydrodynamic radius), one can calculate important structural parameters of the skin
utilizing the APPM, including the average skin aqueous pore radius and the skin porosity to
tortuosity ratio. The APPM has been applied to a broad class of hydrophilic permeants (see
Table 1), for both small molecules and macromolecules, diffusing through LFS-treated skin.
12, 14, 20, 32, 52, 61–63 Although the APPM assumes a single average pore radius, it can be
extended to include: (i) a distribution of aqueous pore radii,32 and (ii) lipophilic pathways.64
There is strong evidence that there is a distribution of skin pore radii, as reflected by the fact
that the size of the permeant used in the context of the APPM affects the average pore radius
calculated.32, 61 In other words, larger permeants can only travel through aqueous pores
that are larger than their hydrodynamic radius. Therefore, macromolecules can only sample
the upper tail of the aqueous pore radius distribution, while smaller permeants have access to
a wider range of pore radii. In addition to the apparent pore radius depending on the size of
the permeant used, the ultrasound amplitude also plays an important role. An examination of
Table 1 shows that most studies conducted in the range 7.2 – 7.5 W/cm2 at 20 kHz
calculated the average skin aqueous pore radius to be close to 100 Å. On the other hand,
studies which utilized 1.0 – 1.6 W/cm2 at 20 kHz generally calculated average skin aqueous
pore radii which are smaller than 35 Å (comparable to the radius of native skin pores). It is
also worth noting that at lower LFS intensities (1.08 W/cm2), no frequency dependence of
the pore radii was observed.32 On the other hand, at higher LFS intensities (7.5 W/cm2),
pore radii were affected significantly by the applied ultrasound frequency.14 The observed
intensity and frequency dependence of pore radii are both likely due to the formation of
larger LTRs at higher ultrasound intensities. Indeed, it is known that large aqueous pores are
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formed almost exclusively within LTRs due to cavitational processes,14, 52, 64 and that
LTR area is inversely proportional to skin resistivity (skin samples with lower skin
resistivities generally possess larger LTRs).14, 52 Therefore, given that the log R values in
Table 1 are lower for the samples treated at higher LFS intensities (7.2 – 7.5 W/cm2), the
larger pores and the observed frequency dependence of pore radii in these skin samples is
due to an increase in LTR area and to a higher level of skin perturbation in these samples,
with respect to samples treated at LFS intensities of 1.0 – 1.6 W/cm2.
The APPM has been very useful to extract information about how various LFS treatment
regimens, both in the presence and absence of chemical enhancers, affects the structural
state of the skin. For example, a recent mechanistic investigation studied pore radii within
LTRs and non-LTRs of LFS-treated skin.14 By showing that the pore radii within LTRs
correlate strongly with the applied LFS frequency, while the pore radii within non-LTRs are
frequency independent, useful conclusions about the enhancement mechanisms operating
within each skin region were drawn (see Section 2.2).14 In addition, utilizing the APPM,
Seto et al. have recently shown that the response of different skin models to the LFS/SLS
treatment is not necessarily the same. Specifically, it was demonstrated that, although full-
thickness and split-thickness pig skin models respond in an equivalent manner to the LFS/
SLS treatment, human skin models of varying thickness do no respond in an identical
fashion.63 In general, the APPM provides a useful tool to understand and analyze the
transport of hydrophilic permeants across the skin, as well as to analyze the structural state
of the skin following LFS treatment.
3.2 LFS-Mediated Transdermal Transport of Hydrophilic Permeants
The ability of LFS to increase skin permeability to hydrophilic permeants has been well
established through research done with the APPM. Simple sugars, such as sucrose and
raffinose (see Table 1), having log octanol-water partition coeffients (log Ko/w) less than
−3,65 and even larger water soluble fibers, such as inulin, have been shown to penetrate
through skin in appreciable amounts following LFS treatment.20, 32, 57, 61, 63 In addition to
allowing the delivery of hydrophilic permeants, LFS skin treatment has also been shown to
allow the extraction of hydrophilic analytes, such as blood glucose (log Ko/w = −3.2465).21,
22, 38, 66 Strict glycemic control is critical for proper care of diabetic patients. By increasing
the permeability of the skin using LFS, followed by the application of a transdermal glucose
sensor, it has been shown that blood-glucose levels can be monitored continuously for up to
24 hours.15, 67 The delivery and extraction of hydrophilic permeants in clinical use will be
discussed further in Section 5.
4. Delivery of Macromolecules Utilizing LFS
The delivery of proteins, biopolymers, nanoparticles, and other high-molecular weight drugs
or particles has received considerable attention during the past few years. However, this
application of LFS is not just a recent trend, but dates back to some of the earliest studies
with LFS.19, 24 The benefit of transdermal protein delivery is that it bypasses the harsh
environment of the gastro-intestinal tract, which can induce protein denaturation and loss of
therapeutic activity. Moreover, compared to injections, it allows for controlled release
profiles (not just a bolus), and displays possible compliance and safety benefits due to the
elimination of needles from the delivery process.1, 2 Therefore, it is not surprising that when
LFS was established as a feasible means of delivering high-molecular weight proteins, some
of the first molecules that were tested included proteins, such as insulin and interferon-γ.19,
24 However, delivery of high-molecular weight molecules by LFS is not only limited to
proteins, but includes high-molecular weight drugs, hormones, fibers, biopolymers,
oligonucleotides, liposomes, nanoparticles, and even vaccines (see Table 2).
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The most widely studied protein, with respect to transdermal delivery by LFS, is insulin (see
Table 2), because of its implications in the treatment of diabetes. After Tachibana et al.
showed the feasibility of transdermal insulin delivery with LFS,24 Mitragotri et al.
conducted the first comprehensive study comparing LFS-mediated insulin delivery with
subcutaneous injection.19 These authors showed that, above a threshold ultrasound intensity
and treatment time, LFS-mediated insulin delivery was as effective at lowering blood
glucose levels as subcutaneous injection, including lowering blood glucose levels of diabetic
rats to normal levels.19 More recently, there has been extensive research on insulin delivery
using a light, portable cymbal array device, which operates at 20 kHz and intensities
between 50 – 100 mW/cm2.36, 37, 39, 40 The novelty of the cymbal array is in its compact
size, being only 3 mm in thickness and varying in surface dimensions between 3 cm×3 cm
and 6 cm×6 cm, which allows the device to be worn during treatment. This could potentially
lead to a closed-loop system, where one wearable device could house both a glucose sensor
and the ultrasound transducer, allowing the delivery of insulin on demand in response to
glucose readings. The feasibility of both insulin delivery36, 37, 39, 40 and glucose sensing38
using the cymbal array device has been tested and validated.
4.1 Transdermal Vaccination
In addition to insulin, another research area that is gaining increased attention is transdermal
vaccination. Transdermal vaccination would provide many advantages over current
hypodermic injection methods of vaccination, because it would completely eliminate safety
concerns involving the use of needles, especially with regards to misuse and improper re-use
in lower-income areas and nations. Furthermore, using a patch vaccine formulation, it may
be possible to expose the body to a lower concentration of antigens for a longer period of
time, which could provide a similar, or stronger, immune response by targeting the
Langerhans cells within the skin, while having the added safety benefit associated with
lower concentrations of antigen encountered by the immune system.68, 69 The first study of
LFS-mediated vaccine delivery was conducted by Tezel et al., and involved the delivery of
tetanus toxoid (TT) into an in vivo mouse model following pretreatment with 20 kHz LFS
and 1% SLS.31 The study found that TT IgG titers increased with increasing LFS energy
density (LFS energy density = LFS amplitude × LFS treatment time), and that the titers
obtained with 1.3 μg of TT delivered by LFS were similar to those obtained by subcutaneous
injection of 10 μg of TT (note that subcutaneous injection of 5 μg of TT is sufficient for
immunity to tetanus toxin). Therefore, the authors concluded that LFS not only elicits an
enhanced immune response because of the increased delivery of TT to the Langerhans cells,
but also through LFS-induced activation of Langerhans cells. In fact, LFS alone, in the
absence of antigen, was found to induce activation of Langerhans cells in these studies.31
Other studies have also shown the ability of high-amplitude LFS (5–7 W/cm2) to induce an
increased immune response, when compared to low-amplitude LFS (0.15 W/cm2) and
negative controls.70 These findings demonstrate the significant potential of LFS to act as a
physical adjuvant, and motivate further investigation of LFS-mediated transdermal
immunization. A more recent study investigated the level of TT antibody titers in mice
treated with LFS, while varying SLS concentrations and ultrasound parameters.28 This study
found that 0.5% SLS provided an immune response superior to that of 1% SLS, despite
causing less skin perturbation. Similarly, a 10% duty cycle produced higher antibody titers
than a 20% duty cycle, in spite of again causing less skin damage.28 Therefore, it is clear
that the mechanisms of immune response by LFS are not well understood, and more
research is needed in order to optimize protocols for transdermal vaccination using LFS.
4.2 Delivery of Nanoparticles
In addition to the delivery of simple molecules, the delivery of nanoparticles and molecules
in liposomal formulations have also been tested with LFS (see Table 2). With respect to
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mechanistic investigations, quantum dots (QDs) have been utilized in several studies,
because it is possible to tune their size and surface chemistry in a controlled fashion.63, 71,
72 A recent study by Lopez et al. investigated the delivery of QDs (10–22 nm in diameter),
with varying surface charge (cationic, neutral, and anionic), in order to evaluate LFS
treatment to enhance skin penetration of transdermal carriers.71 Lopez et al. found that the
LFS treatment increased the amount of QDs penetrating past the epidermis by 500–1300%.
Interestingly, however, the highest charged cationic QD did not penetrate the most, as
originally expected, suggesting that there is an optimal cationic surface charge for designing
transdermal carriers.71 Other studies have considered the delivery of metallic nanoparticles
into LFS-treated skin, including gold nanoparticles63 and iron oxide nanoparticles.48 The
latter study, utilizing iron oxide nanoparticles, was conducted using zero clearance between
the skin surface and the ultrasound horn, which is not typical of treatment protocols
involving LFS. In general, it is advisable to leave some clearance between the skin and the
ultrasound horn, even if it is a small distance (2–3 mm), to avoid the creation of pockets of
air/coupling solution between the skin and the ultrasound horn. Without any clearance, small
solution volumes trapped between the skin and the ultrasound horn, which are restricted
from mixing with the bulk solution, could heat rapidly. This heating can cause thermal
effects that are unaccounted for and could lead to difficulty in the interpretation of the
mechanisms of enhancement.
Larger particles have also been delivered through LFS-treated skin, the majority of which
are liposomal formulations. Liposomal formulations are a natural delivery vehicle in the
context of LFS-mediated transdermal delivery, because formulations of lidocaine within
liposomes are already clinically used for topical anesthesia, which will be discussed further
in Section 5 (see Table 3). An interesting application of liposomal formulations has been
reported by Tran et al. for the delivery of siRNA-liposome complexes for treatment of
melanoma.41 The study showed that the application of LFS enabled the delivery of loaded
cationic liposomes throughout the epidermis and the dermis of skin reconstructs, as well as
in an in vivo mouse model, which led to a decrease of melanoma by a statistically significant
amount.41 Other studies have examined the delivery of liposomes or microparticles as large
as 173 μm in diameter,27, 73 and have shown that particles as large as 25 μm in diameter can
penetrate the skin.73 However, the study involving the delivery of microparticles as large as
173 μm was conducted at extremely high amplitudes, approximately 3 – 7-fold higher (19 –
49 W/cm2) than the highest amplitudes commonly used for LFS-mediated transdermal
delivery (7 – 8 W/cm2). Therefore, although particles as large as 25 μm in diameter were
delivered through heat-stripped skin, microscopy showed macroscopic holes in the skin,73
which casts significant concern with regards to the safety of this treatment protocol. Under
typical LFS conditions, which have been tested for safety, it is generally believed that
particles no larger than ~100 nm can penetrate LFS-treated skin as intact entities (see Table
2).
5. Clinical Applications of LFS
LFS has been utilized in many clinical applications for the delivery and extraction of
different types of drugs and analytes (see Table 3), in addition to being used for cosmetic
purposes in skin rejuvenation and cellulite remediation. Here, we will focus solely on
clinical applications relevant to drug delivery and analyte extraction. The first clinical
application of LFS involved the delivery of liposomal lidocaine, or lidocaine/prilocaine
(both are small, hydrophobic molecules), to decrease the time of onset for local anesthesia.17
This application has been well documented, with multiple pilot and clinical trials showing
that LFS decreases the onset to anesthesia with lidocaine, from 30–60 minutes passively, to
less than 5 minutes with LFS pretreatment. This technology is FDA approved for use in both
adults and children for local anesthesia prior to hypodermic injection, IV cannulation, and
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blood donation (SonoPrep®, Echo Therapeutics, Franklin, MA, see Figure 4).16, 17, 74–76
The device has also been tested for use in combination with iontophoresis, which results in
an even shorter time to onset of anesthesia (2 minutes).18 Other applications of the device
involve the extraction of interstitial fluid for blood-glucose and lactate monitoring, which is
currently in the process of attaining FDA approval.15, 67
Other studies have investigated the delivery of hydrophilic molecules in clinical applications
(see log Ko/w values in Table 3), including the delivery of histamine,77 kojic acid,78
ascorbic acid,78 and epinephrine.18 Additionally, cyclosporine solution (MW = 1203 kDa)
has been utilized in combination with LFS for the treatment of alopecia areata.78 In all
cases, the drugs delivered were reported to have the desired effect. For complete
experimental details of clinical trials, refer to Table 3.
6. Safety of LFS
The safety of LFS for use in animals and humans has been evaluated rather rigorously for
single dose applications. Clinical studies with the SonoPrep® device have shown that,
following a single treatment (~10 seconds), there are usually minimal or no adverse
reactions, with the most common side effect being mild erythema.16, 17, 74–76 As stated
above, the SonoPrep® has therefore been FDA approved for use in children and adults for
decreasing the onset time to local anesthesia. The effect of LFS on animal models and
cultured cell lines has also shown that the use of low ultrasound intensities is safe, causing
no changes in skin pathology and cell viability.19, 22, 26, 70, 79 In general, for single
application treatments, thermal effects caused by LFS are of most consequence to the skin if
not monitored properly, causing potentially serious side effects such as burns, epidermal
detachment, epidermal or dermal necrosis, and, on a cellular level, keratinocyte apoptosis.70,
79 However, these types of side effects are easily mitigated by minimizing the duration and
intensity of the LFS treatment utilized.
Although LFS has been generally accepted as safe for single dose uses, there have been no
significant studies of the prolonged or repeated use of such treatments. These types of
studies will need to be conducted to establish the safety of LFS in the treatment of chronic
diseases. For example, the current application of non-invasive blood glucose monitoring
would require daily LFS treatment, as would other drug delivery applications. Therefore,
sustained in vivo safety studies are needed to understand the potential skin toxicities
involved with repeated LFS treatment.
7. Conclusion
Low-frequency sonophoresis (LFS) has been shown to allow transdermal delivery of both
hydrophilic and high-molecular weight permeants at therapeutic levels. LFS is known to
increase the permeability of skin through the process of acoustic cavitation above the skin,
which causes the formation of acoustic microjets on the surface of the skin in a non-uniform
manner. The heterogeneous occurrence of cavitation leads to the formation of localized-
transport regions (LTRs), which have much higher permeability than the surrounding non-
LTRs. When a chemical enhancer, such as the surfactant sodium lauryl sulfate, is included
in the treatment of skin with LFS, a very strong synergistic enhancement in skin
permeability is observed. This enhancement in skin permeability allows delivery of
hydrophilic permeants, whose transport through the skin can be explained in the context of
the aqueous porous pathway model (APPM). Additionally, LFS-mediated transdermal
delivery can also be utilized to deliver macromolecules, including proteins, hormones,
biopolymers, fibers, vaccines, liposomes, and even nanoparticles. This technology has been
tested in clinical trials, and is currently FDA approved for use with local anesthetics. In
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addition, the technology has the potential to deliver a broad class of drugs in a manner that
avoids side effects associated with oral delivery and transcutaenous injection. However,
further research is necessary to better understand and control the reproducibility and safety
of the ultrasound parameters used in clinical treatment. A potential exciting area of future
research involves LFS-mediated transdermal vaccination, because it has been shown that
LFS itself can act as a physical adjuvant.
8. Expert Opinion
The use of LFS has shown great promise in the transdermal delivery of therapeutics,
including hydrophilic drugs and macromolecules. Since the initial investigations of
transdermal delivery utilizing ultrasound frequencies between 20 and 100 kHz two decades
ago, this technology has already spawned a number of startups, received FDA approval for
the topical delivery of local anesthetics, and is currently being investigated for other clinical
applications, such as skin permeabilization for non-invasive blood glucose monitoring. With
this strong beginning, LFS-mediated transdermal delivery has the potential to gain an even
stronger clinical foothold by exploiting the unique strengths of this technology. For
example, LFS can be utilized for systemic, regional, and local delivery, with the ability to
control the transdermal delivery profile of the active therapeutic compound by varying the
ultrasound treatment parameters. Therefore, in addition to the systemic delivery of proteins,
such as insulin, local delivery of drugs to treat skin disorders may be an area where LFS can
exploit its ability to permeabilize skin in a controlled manner. This may be particularly
relevant to skin disorders where the delivery of active therapeutics through the skin
represents a limiting transport step, and the number of side effects can be limited by
localized therapy, such as in the case of psoriasis plaques.80, 81
Another application where LFS may be able to distinguish itself from other physical skin
permeability enhancers is in the development of a closed-loop system for the monitoring of
blood analytes and the subsequent delivery of appropriate therapeutics. The advancement of
the cymbal array device by Smith et al.40 has now opened the door to a wearable LFS
device. Additionally, the feasibility of LFS for non-invasive blood-glucose monitoring has
already been established.15, 21, 67 Therefore, the technology necessary to create such a
device already exists. Nevertheless, many obstacles still need to be overcome before a
device is ready for use in the clinic. For example, potential challenges include the
development of efficient algorithms involved in sensing and delivery (because there is a lag-
time associated with both transdermal blood-glucose monitoring and the transdermal
delivery of insulin, accurate predictions will be crucial), and in the design of a battery
system that would be powerful enough to drive the LFS cymbal array, while still being small
enough to allow for a wearable device.
A final exciting area where LFS could have a significant impact is in the field of transdermal
vaccination. The feasibility of transdermally delivering high-molecular weight vaccines,
such as tetanus toxoid, by LFS has already been established in in vitro and in vivo animal
models.28, 31 It is also known that targeting of the Langerhans cells in the skin can result in
an enhanced immune response with respect to vaccine injection.68, 82 However, in addition
to allowing increased amounts of antigens to reach the Langerhans cells by increasing skin
permeability, the LFS treatment itself has been shown to activate the Langerhans cells and
elicit an immune response.31, 70 In fact, Tezel et al. have shown that the immune response
induced by the delivery of 1.3 μg of tetanus toxoid (TT) to the Langerhans cells by LFS is
equal to that of 10 μg of TT injected subcutaneously in mouse models.31 Clearly, more
research is needed to fully understand, characterize, and control this effect. This would
involve not only studying delivery of antigens and the resulting immune response, but also
the formulation of vaccines for delivery via the transdermal route. An additional variable
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that could also be studied is the addition of a co-enhancer during the LFS treatment, because
it has been shown that the immune response elicited by tetanus toxoid can increase with the
inclusion of SLS in the LFS coupling medium, although the response is not directly
proportional to the SLS concentration.28
In addition to the specific areas discussed above, additional research is needed on the
general safety of the technology. If a closed-loop device for glucose monitoring and insulin
delivery is developed, long-term safety studies are necessary to determine whether repeated
treatments with LFS are safe. Current safety studies have only been conducted for relatively
short times (a maximum of 24 – 48 hours), and usually following only a single LFS
treatment. Moreover, if drugs are to be systemically and repeatedly delivered by LFS, more
research is needed into the reproducibility of skin permeability induced by the LFS
treatments, both between different patients and after repeated treatments in a single patient.
Additionally, further research on the generation of more uniform skin permeability
enhancement would greatly benefit LFS treatments. Under current treatment protocols with
SLS, only 5–25% of the skin surface treated by LFS contains LTRs, which are the skin
regions through which the majority of transdermal transport occurs (see Figure 3).57 If one
could increase the size of the LTRs to cover the entire skin surface treated, the area of skin
treatment sites could decrease by up to 20-fold. This would result in decreased power
needed to operate the LFS device and aid in further miniaturization of a clinical device. For
example, Paliwal et al. have recently shown that an aqueous mixture of 0.5% 3-(decyl
dimethyl ammonio) propane sulfonate and polyethylene glycol dodecyl ether induced three
times more LTR area than 1% SLS.83 Therefore, research on cavitation enhancers for use
with LFS, including more potent synergistic chemical enhancers, deserve further
investigation.
In conclusion, LFS-mediated transdermal delivery of hydrophilic drugs and macromolecules
shows great promise to address key needs in the medical field, such as developing a closed-
loop system for tighter glycemic control, treating localized skin disorders, and transdermal
vaccination. However, there are still opportunities to make technological and mechanistic
advances with this technology that can increase its clinical utility. To reach the ultimate goal
of positively affecting patients' lives, LFS researchers must focus on the unique advantages
offered by LFS, including exploiting these advantages when investigating new treatments
involving LFS.
Article Highlights Box
- Introduction – The general field of transdermal drug delivery, its benefits over
other delivery methods, and the structure and barrier properties of the skin are
introduced.
- Background – Background into the mechanisms of enhancement by low-
frequency sonophoresis (LFS) and observed phenomena in skin treated by LFS
are presented.
- Delivery of Hydrophilic Permeants with Low-Frequency Sonophoresis –
Theoretical models and experimental methods utilized in the delivery of
hydrophilic permeants with LFS are discussed.
- Delivery of Macromolecules Utilizing Low-Frequency Sonophoresis – Research
involving LFS-mediated delivery of high-molecular weight molecules and
nanoparticles is analyzed.
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- Clinical Applications of Low-Frequency Sonophoresis – Current use of LFS
technology in patients and applications of the LFS technology that are under
investigation for regulatory approval are discussed.
- Safety of LFS – Issues related to the safety of LFS treatment are examined.
- Expert Opinion – Exciting current and future applications are examined,
including transcutaneous immunization and a closed-loop system for glycemic
control, including other forward looking statements.
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Figure 1.
Cross-sectional schematic of the stratified layers of the epidermis. The stratum corneum
provides the skin with the majority of its barrier properties, being comprised of anucleate
corneocytes embedded in a lipid matrix. Legend: corneocytes ( ), keratinocytes with a
nucleus ( ), keratinocytes containing granules ( ), and lipids ( ).
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Figure 2.
Two-photon microscopy image of the honeycomb structure of the stratum corneum. The
lipid bilayers are stained with the fluorescent dye rhodamine B – hexyl ester. The dark,
approximately hexagonal, regions are the highly cross-linked corneocytes, where the dye
cannot penetrate deeply.
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Figure 3.
Localized transport regions (LTRs) on the surface of low-frequency ultrasound and ethanol
treated skin, as visualized with allura red staining.
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Figure 4.
Low-frequency ultrasound treatment in a clinical setting with the SonoPrep® device (Echo
Therapeutics, Franklin, MA). The patient holds a conductive polymer hand-piece and the
device automatically stops when the skin impedance is decreased to the desired treatment
level. Usual treatment times are on the order of 10 seconds (reprinted with permission from
Ref. 87).
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